All News
#ACR25 Beyond blinatumomab, A-319, CD3xCD19 BiTE in 12 patients with #SLE in China reported dose-dependent depth of B-Cell depletion but not efficacy or safety. One withdrew due to AE. No CRS/ICANS. Be interested to see results in larger trials & longer follow-up @RheumNow https://t.co/e5RuZlFI6i
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#ACR25 Abstr#776 2-Year SELECT-GCA RCT showed that #GCA patients receiving continuous UPA15 to 2-yr maintained their remission (69%) vs those who switched to PBO after in remission for ≥24 weeks (29%). Lower serious infection but higher herpes zoster in UPA15. One VTE @RheumNow https://t.co/FCTNqCVxiZ
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Lindberg et al. Nationwide case-control study in Sweden. Big increase in risk of DVT/PE in AAV, most marked early after diagnosis @RheumNow #ACR25 Abstr#718 https://t.co/FpDcbX15hm
Richard Conway RichardPAConway ( View Tweet)
Heydari-Kamjani et al. Risk of DILI with avacopan. Real world study, propensity score matching. Risk DILI 2% with avacopan vs 1.9% PBO @RheumNow #ACR25 Abstr#724 https://t.co/UhVkcXEYjF
Richard Conway RichardPAConway ( View Tweet)
2-Year data from SELECT-GCA Phase 3 UPA in GCA
Re-randomization & 52 weeks extension UPA 15mg vs. PBO
-Risk of flare 90% lower
-Complete remission 70% vs 20%
-Cumulative GC 1g difference
-No new safety signal
The quick relapse after stopping UPA indicates we are really looking https://t.co/c1khywnPNv
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
SELECT-GCA (upadacitinib in GCA for 52w)
we hoped it might have ongoing effect post-cessation
Do we need to continue upa?
Extension data (second year) flare survival curves are clear:
continuing upa far outperforms placebo
It seems >2y toci/upa for GCA
#ACR25 ABST0776 @RheumNow https://t.co/uJA3uQyWxb
David Liew drdavidliew ( View Tweet)
#0776
In the 2-yr SELECT-GCA trial, continued upadacitinib 15mg maintained remission in 69% vs 29% who switched to PBO, cutting flare risk by 90% and reducing steroid exposure by ~1g.
No new safety signals in older adults (mean 71yrs). @RheumNow #ACR25 https://t.co/KC9sm3ic3q
Mrinalini Dey DrMiniDey ( View Tweet)
RheumNow’s expanded coverage of the #ACR2025 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is independently selected by RheumNow and its faculty.
Dr. John Cush RheumNow ( View Tweet)
Schmidt et al. 2 year results of SELECT-GCA, upadacitinib in GCA. Remission 69% if upa continued vs 29% if stopped. 90% lower risk of flare, 1G less steroid @RheumNow
#ACR25 Abstr#0776 #ACRBest https://t.co/MgRo7kIgIw
Richard Conway RichardPAConway ( View Tweet)
Statins and SLE: To add or not to add? 💊
Abstract #0599: In an emulated target trial of patients with SLE, statin users vs non-users had significantly⬇️ risk of all-cause death in both ITT & per-protocol analyses.
- No significant differences in MACE or ESKD.
@RheumNow #ACR25
Akhil Sood MD, MS AkhilSoodMD ( View Tweet)
Mease et al. Sometimes perspective is all important! We worry about apremilast causing GI effects, anorexia, weight loss. Here we see reported benefits for weight loss and HbA1c. @RheumNow #ACR25 Abstr#581 https://t.co/CJjS0VZxWH
Richard Conway RichardPAConway ( View Tweet)
Plenary 1: SELECT-GCA (RCT, UPA vs PLBO in GCA)
Pts in remission re-randomized at wk52
Higher maintenance of remission in pts who continued UPA15 (69%) vs switchers from UPA15->PLBO (29%)
Argues strongly for continuing tx in GCA for >1yr!
@RheumNow #ACR25 Ab#0776 #ACRBest https://t.co/exmmIcpgbP
Links:
Mike Putman EBRheum ( View Tweet)
How does cMRI change over time in cardiac EGPA?
Cheng et al. retrospectively reviewed:
- 11 EGPA pt with LGE on initial cMRI
Despite treatment:
- 10/11 persistent LGE on 2nd cMRI
- 4/4 on 3rd
- 2/2 on 4th
Unclear use as a monitor of tx response
@RheumNow #ACR25
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
#0773 Anti-MDA5 epitope mapping identifies key regions (aa 201-300, 601-700) linked to treatment resistance & poor prognosis in DM-ILD and even IIPs.
Epitope-specific antibodies could refine risk stratification & guide therapy in ILD beyond autoimmune disease. @RheumNow #ACR25 https://t.co/moRffVGZPn
Mrinalini Dey DrMiniDey ( View Tweet)
#AI for medical use is fast moving
governance is Impt
Protect Privacy
Facilitate trainees to LEARN
Involve #IT, ethicists, users
‘We will enter a world where all we do medically is recorded’ J Hausmann said
#ACR25 @RheumNow @ACRheum
#26S17 https://t.co/zWjy4u99Yo
Janet Pope Janetbirdope ( View Tweet)
#Medical #learners more optimistic re #AI than gen pop’n!
Tips
stress privacy
- pt info in AI goes to private company
All trainees will use #AI
Set boundaries - change eval where can’t use AI
only AI listening notes
👇
#cognitive #deskilling
#ACR25 @RheumNow @ACRheum
26S17 https://t.co/UzajaimOcG
Janet Pope Janetbirdope ( View Tweet)
@ACRheum SLE Treatment Guidelines 2025
Key points:
- HCQ is standard
- steroids with precision
- immunosuppressive therapies early
- shared decision making
#ACR25 @RheumNow https://t.co/AYIXE6dLlW
David Liew drdavidliew ( View Tweet)
Saphnelo (anifrolumab) has been recommended for approval in EU by CHMP for systemic lupus erythematosus (on top of standard therapy) as a once-weekly pre-filled pen.
Recommendation based on TULIP-SC Phase III trial. https://t.co/UurvtLNP7S https://t.co/xeKVdVYu3z
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #ACR25 Annual Meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is independently selected by RheumNow and its faculty.
Dr. John Cush RheumNow ( View Tweet)
Telitacicept Effective in Systemic Lupus Erythematosus
The NEJM has published a report from van Vollenhoven et al showing a new dual B cell inhibitor, telitacicept, to be effective when given to active systemic lupus erythematosus (SLE) patients; but this comes with a few https://t.co/L0TgynLELD
Dr. John Cush RheumNow ( View Tweet)
